DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Acular (Ketorolac Tromethamine Ophthalmic) - News

 
 



News related to Acular (Ketorolac Ophthalmic) and/or conditions it is approved for

VEGF Inhibition Improves Visual Acuity in Macular Edema
Source: Medscape Medical News Headlines [2014.04.12]
Ranibizumab improved visual acuity at 6 months in patients with macular edema secondary to ischemic branch retinal vein occlusion, whether or not they underwent laser photocoagulation.
Medscape Medical News

Scientists have discovered a potentially novel form of therapy for Age-Related Macular Degeneration that uses a component of our immune system
Source: Eye Health / Blindness News From Medical News Today [2014.04.04]
Scientists at Trinity College Dublin have made a major breakthrough with important implications for sufferers of the eye disease Age-Related Macular Degeneration (AMD), which can cause central...

Macular Degeneration
Source: MedicineNet Cataracts Specialty [2014.01.23]
Title: Macular Degeneration
Category: Diseases and Conditions
Created: 7/23/1999 6:05:00 PM
Last Editorial Review: 1/23/2014 12:00:00 AM

Jetrea Gets FDA Nod for Macular Adhesion
Source: MedPage Today Product Alert [2012.10.19]
WASHINGTON -- The FDA has approved ocriplasmin (Jetrea) as the first nonsurgical treatment for symptomatic vitreomacular adhesion.

'Miniature Telescope' for Eye Approved for Macular Degeneration
Source: MedicineNet Macular Degeneration (Age-Related Type) Specialty [2010.07.07]
Title: 'Miniature Telescope' for Eye Approved for Macular Degeneration
Category: Health News
Created: 7/6/2010 2:10:00 PM
Last Editorial Review: 7/7/2010

Major breakthrough in eye disease therapy
Source: Eye Health / Blindness News From Medical News Today [2014.04.04]
A major breakthrough has been made by scientists at Trinity College Dublin, with important implications for sufferers of the eye disease Age-Related Macular Degeneration (AMD), which can cause...

Ruboxistaurin (RBX) may reduce risk of vision loss in diabetics
Source: The Doctors Lounge - Endocrinology and Diabetes
Phase III trial demonstrates ruboxistaurin (RBX) may reduce the risk of vision loss especially in diabetic macular edema.

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2012